a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

ConditionsMultiple Myeloma Neoplasm, Plasma Cell Multiple Myeloma in Relapse

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorChongqing Precision Biotech Co., Ltd

About this trial

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Eligibility criteria

Qualifiers

Signed written informed consent;

Failed to standard chemotherapy regimens;

Relapse after complete remission, high-risk and / or refractory patients ;

Relapse after hematopoietic stem cell transplantation;

Disqualifiers

Previous history of other malignancy;

Presence of uncontrolled active infection;

Evidence of disorder that need the treatment by glucocorticoids;

Active or chronic GVHD

Trial design

Treatments tested in this trial

BCMA targeted prime CAR-T cells

Treatment groups

80 Participants

are divided into 1 treatment group

Sponsors and collaborators

Chongqing Precision Biotech Co., Ltd

Lead sponsor

Source ClinicalTrials.gov